Abstract 4912
Background
AK104 is a tetravalent bispecific human IgG1 antibody, targeting two clinically validated receptors, PD-1 and CTLA-4. This bispecific antibody is designed based on Akeso Tetrabody platform (AACR, 2018). AK104 introduces novel T cell targeting MOAs that may provide an improved therapeutic index and a favorable toxicity profile when compared to the PD-1 and CTLA-4 combinations. In addition, we have shown increased avidity of AK104 binding to PD-1 and CTLA-4 compared to the combinations. The combination therapy with anti-PD-1 and anti-CTLA-4 agents is approved by FDA for metastatic melanoma, renal cell carcinoma and MSI-H/dMMR colorectal cancer. The efficacy of these drug combinations is dose dependent, and the toxicity associated with anti-CTLA-4 agents in particular is dose limiting, thereby potentially limiting full potential for combination therapy. Despite recent advances, the prognosis of patients with advanced gastric cancer remains poor. AK104 may show improved efficacy and safety in comparison to the combination of conventional anti-PD-1/L1 and anti-CTLA-4 antibodies.
Trial design
This multicenter, open-label, phase Ib/II study will evaluate the safety and efficacy of AK104 in combination with oxaliplatin and capecitabine (mXELOX) as first-line therapy in patients with advanced gastric or GEJ adenocarcinoma. The dose-escalation phase will evaluate three dose levels (4mg/kg, 6mg/kg, and 10mg/kg Q2W) to identify a maximum tolerated dose (MTD). Selected cohorts will be expanded up to a total of 18 patients per cohort to further establish the recommended Phase 2 dose (RP2D). Dose escalation and expansion phase will be followed by dose confirmation phase (Phase II) which will further characterize the treatment of AK104 in combination at RP2D. The primary endpoints are safety and efficacy (ORR in Phase II). Secondary endpoints include additional efficacy (PFS, DoR), pharmacokinetics, PD and immunogenicity. Exploratory endpoints include efficacy according to immune-related RECIST and correlations between potential biomarkers (PD-L1 expression, TMB) and clinical activity.
Clinical trial identification
NCT03852251.
Editorial acknowledgement
Legal entity responsible for the study
Peking University Cancer Hospital & Institute, Beijing, China.
Funding
Akeso Biopharma, Inc., Zhongshan, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1058 - Assessment of CPS+EG, Neo-Bioscore and modified Neo-Bioscore in breast cancer patients treated with preoperative systemic therapy: a multicenter cohort study
Presenter: LING XU
Session: Poster Display session 2
Resources:
Abstract
1156 - The concordance of treatment decision guided by Oncotype and the PREDICT tool in early stage breast cancer
Presenter: Hadar Goldvaser
Session: Poster Display session 2
Resources:
Abstract
3447 - Influence of first treatment delay on survival among breast cancer subtypes
Presenter: Irene Zarcos Pedrinaci
Session: Poster Display session 2
Resources:
Abstract
3505 - Clinical features of early-stage (I-III) triple-negative breast cancer (TNBC) patients with tumors exhibiting low-overall change in molecular profile after neoadjuvant therapy.
Presenter: Nour Abuhadra
Session: Poster Display session 2
Resources:
Abstract
5442 - Meta-analysis in HER2+ early breast cancer therapies and cost-effectiveness in a Brazilian perspective
Presenter: Marcos Magalhaes
Session: Poster Display session 2
Resources:
Abstract
1570 - Anti-mullerian hormone (AMH) levels and antral follicle counts (AFC) may predict ovarian reserves before systemic chemotherapy (SC) in women with breast cancer(BC); a prospective clinical study
Presenter: Cetin Ordu
Session: Poster Display session 2
Resources:
Abstract
2698 - Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.
Presenter: Giuseppe Cancello
Session: Poster Display session 2
Resources:
Abstract
3104 - Novel Blood Based Circulating Tumor Cell Biomarker For Breast Cancer Detection
Presenter: Chun-Yu Liu
Session: Poster Display session 2
Resources:
Abstract
4631 - Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response of ER-Positive HER2-Negative Breast Cancer Patients to Neo-Adjuvant Chemotherapy
Presenter: Claudia Mazo
Session: Poster Display session 2
Resources:
Abstract
4632 - Impact of menopause status on breast cancer outcomes and amenorrhea incidence during adjuvant tailored dose dense chemotherapy
Presenter: Andri Papakonstantinou
Session: Poster Display session 2
Resources:
Abstract